OncoMatch/Clinical Trials/NCT07062549
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
Is NCT07062549 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies 111In-XYIMSR-01 for renal cell carcinoma (kidney cancer).
Treatment: 111In-XYIMSR-01 — This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Renal Cell Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: systemic therapy
Systemic therapy for the treatment of ccRCC within 12 months of study enrollment.
Cannot have received: radioisotope
Subjects administered any radioisotope within five physical half-lives prior to study drug injection.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500 /mm3; Platelets ≥100,000/ mm3; Hemoglobin ≥ 9.0 g/dL; White blood cell count ≥ 2,000/ mm3
Kidney function
Creatinine clearance ≥50 mL/min based on Cockcroft-Gault formula
Liver function
Serum bilirubin ≤ 1.5x ULN (≤ 3x ULN for Gilbert's syndrome); ALT ≤ 3x ULN; AST ≤ 3x ULN
Screening clinical laboratory values as specified below: * Serum bilirubin ≤ 1.5 times the upper limit of normal; for patients with known Gilbert's syndrome, ≤ 3 × ULN is permitted * ALT ≤ 3 times the upper limits of normal * AST ≤ 3 times the upper limits of normal * Creatinine clearance ≥50 mL/min based on Cockcroft-Gault formula * Absolute neutrophil count ≥ 1,500 /mm3 * Platelets ≥100,000/ mm3 * Hemoglobin ≥ 9.0 g/dL * White blood cell count ≥ 2,000/ mm3
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins University · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07062549 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy, radioisotope disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages